Shares in Anika Therapeutics (NSDQ:ANIK) fell today, even though the orthopedic medicines company beat expectations on Wall Street with its 4th quarter results.
The Bedford, Mass.-based company posted profits of $8.1 million, or 54¢ per share, on sales of $28.7 million for the 3 months ended Dec. 31, for bottom-line loss of -26% on sales loss of -7% compared with the same period last year.
Adjusted to exclude 1-time items, earnings per share were 54¢, a penny ahead of consensus on The Street, where analysts were looking for sales of $27.8 million.
Get the full story at our sister site, Drug Delivery Business News.
The post Anika beats Q4 earnings, revenue estimates appeared first on MassDevice.